{"id":1534,"date":"2019-12-06T13:00:00","date_gmt":"2019-12-06T13:00:00","guid":{"rendered":"https:\/\/oncopeptides.com\/mfn_news\/oncopeptides-ab-oncopeptides-haller-en-webcast-tisdagen-den-10-december-klockan-1300-cet-avseende-data-som-presenteras-vid-ashs-arsmote\/"},"modified":"2026-02-23T13:18:25","modified_gmt":"2026-02-23T13:18:25","slug":"oncopeptides-ab-oncopeptides-haller-en-webcast-tisdagen-den-10-december-klockan-1300-cet-avseende-data-som-presenteras-vid-ashs-arsmote","status":"publish","type":"mfn_news","link":"https:\/\/oncopeptides.com\/sv\/pressmeddelanden\/oncopeptides-ab-oncopeptides-haller-en-webcast-tisdagen-den-10-december-klockan-1300-cet-avseende-data-som-presenteras-vid-ashs-arsmote\/","title":{"rendered":"Oncopeptides AB: Oncopeptides h\u00e5ller en webcast tisdagen den 10 december klockan 13:00 (CET) avseende data som presenteras vid ASH:s \u00e5rsm\u00f6te"},"content":{"rendered":"<div class=\"mfn-preamble\"><strong><\/p>\n<p class=\"mfn-wp-retain\">Stockholm &#8211; 6 december 2019 &#8211; Oncopeptides AB (Nasdaq Stockholm: ONCO), meddelar idag att bolaget kommer att h&aring;lla en webcast tisdagen den 10 december 2019, kl. 13:00 (CET) f&ouml;r att kommentera de data som presenteras vid det &aring;rliga amerikanska hematologim&ouml;tet (ASH) 7-8 december. Webcasten kommer att h&aring;llas av VD Jakob Lindberg.<\/p>\n<p><\/strong><\/div>\n<p class=\"mfn-wp-retain\">Webcasten kan f&ouml;ljas via l&auml;nken nedan:<\/p>\n<p class=\"mfn-wp-retain\"><a href=\"https:\/\/tv.streamfabriken.com\/oncopeptides-webcast-post-ash\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/tv.streamfabriken.com\/oncopeptides-webcast-post-ash<\/a><\/p>\n<p class=\"mfn-wp-retain\">Deltagare som vill st&auml;lla fr&aring;gor kan ringa in p&aring; de nedanst&aring;ende telefonnumren:<\/p>\n<p class=\"mfn-wp-retain\">Sverige: + 46 8 56642706<br \/>Europa: + 44 3333009270<br \/>USA: + 1 8335268384<\/p>\n<p class=\"mfn-wp-retain\">Presentationen kommer att finnas tillg&auml;nglig under:<\/p>\n<p class=\"mfn-wp-retain\"><a href=\"https:\/\/oncopeptides.se\/sv\/post-ash-webcast-2019\/\" rel=\"nofollow noopener\" target=\"_blank\">https:\/\/oncopeptides.se\/sv\/post-ash-webcast-2019\/<\/a><\/p>\n<p class=\"mfn-wp-retain\">&nbsp;<\/p>\n<p class=\"mfn-wp-retain\">F&ouml;r ytterligare information kontakta:<\/p>\n<p class=\"mfn-wp-retain\">Rein Piir, chef f&ouml;r Investor Relations vid Oncopeptides<br \/>E-post: rein.piir@oncopeptides.com<br \/>Mobiltelefon: +46 (0) 70 853 72 92<\/p>\n<p class=\"mfn-wp-retain\">Information l&auml;mnades f&ouml;r offentligg&ouml;rande den 6 december 2019 kl.14:00.<\/p>\n<p class=\"mfn-wp-retain\">Om Oncopeptides<br \/>Oncopeptides &auml;r ett l&auml;kemedelsf&ouml;retag med inriktning p&aring; utveckling av riktade terapier f&ouml;r sv&aring;rbehandlade hematologiska sjukdomar. Bolaget fokuserar p&aring; utvecklingen av produktkandidaten melflufen, ett peptidl&auml;nkat l&auml;kemedel som snabbt levererar ett cellgift till tum&ouml;rceller. Melflufen utvecklas som en ny behandling av den hematologiska cancersjukdomen multipelt myelom och testas f&ouml;r n&auml;rvarande i flertal kliniska studier inklusive den pivotala fas 2-studien HORIZON och den p&aring;g&aring;ende fas 3-studien OCEAN. Oncopeptides har huvudkontor i Stockholm och &auml;r noterat i Mid Cap-segmentet p&aring; Nasdaq Stockholm med kortnamn ONCO.<\/p>\n<p class=\"mfn-wp-retain\">F&ouml;r mer information bes&ouml;k www.oncopeptides.com.<\/p>\n<div class=\"mfn-footer\"><\/div>\n<script>\n                Array.prototype.slice.call(document.querySelectorAll(\".mfn-footer.mfn-attachment\")).forEach(function (el) { el.remove() });\n            <\/script>\n        <div class=\"mfn-attachments-container\"><div class=\"mfn-attachment mfn-file-type-pdf\"><a class=\"mfn-attachment-link\" target=\"_blank\" href=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F2984910%2F1157432.pdf\" rel=\"noopener\"><span class=\"mfn-attachment-icon\"><img decoding=\"async\" src=\"https:\/\/storage.mfn.se\/proxy\/pdf.pdf?url=https%3A%2F%2Fmb.cision.com%2FMain%2F15404%2F2984910%2F1157432.pdf&type=jpg\"><\/span>PDF<\/a><\/div><\/div>","protected":false},"excerpt":{"rendered":"<p>Stockholm &#8211; 6 december 2019 &#8211; Oncopeptides AB (Nasdaq Stockholm: ONCO), meddelar idag att bolaget kommer att h&aring;lla en webcast tisdagen den 10 december 2019, kl. 13:00 (CET) f&ouml;r att kommentera de data som presenteras vid det &aring;rliga amerikanska hematologim&ouml;tet (ASH) 7-8 december. Webcasten kommer att h&aring;llas av VD Jakob Lindberg. Webcasten kan f&ouml;ljas via [&hellip;]<\/p>\n","protected":false},"featured_media":0,"template":"","news_categories":[],"mfn-news-tag":[174,171,180],"class_list":["post-1534","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"_links":{"self":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news\/1534","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/media?parent=1534"}],"wp:term":[{"taxonomy":"news_categories","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/news_categories?post=1534"},{"taxonomy":"mfn-news-tag","embeddable":true,"href":"https:\/\/oncopeptides.com\/sv\/wp-json\/wp\/v2\/mfn-news-tag?post=1534"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}